CHMP recommends label expansion for Stivarga

Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Bayer's (BAYRY) (BAYZF) Stivarga (regorafenib) as a treatment for adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. Stivarga is currently approved for the treatment of metastatic colorectal cancer (mCRC).

CHMP's decision is based on a Phase 3 clinical trial that showed a statistically significant improvement in progression-free survival (PFS) in patients receiving regorafenib plus best supportive care (BSC) compared to patients receiving placebo plus BSC. Median PFS in the test group was 4.8 months versus 0.9 months in the control arm.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs